PHARMA
PHARMAPharmaceutical Hydrogenation Membrane in China
Catalytic hydrogenation is a critical step in active pharmaceutical ingredient (API) synthesis. China operates the world's largest alkaline electrolyser manufacturing base and is the dominant market for AWE systems globally.
Market Context
ChinaPolicy
H₂ Target
Cities
Industries
Ultra-Clean Hydrogen Source
Electrolytic hydrogen from water splitting is inherently free of carbon monoxide, sulfur, and hydrocarbon impurities that can poison precious metal hydrogenation catalysts used in API manufacturing.
GMP-Compatible On-Site Generation
On-site electrolysis provides a controlled, traceable hydrogen source that simplifies GMP documentation and qualification versus multi-sourced delivered gas.
Batch-Flexible Operation
Pharmaceutical manufacturing operates in batches. IONZERA's high wettability supports start-stop operation, generating hydrogen only when hydrogenation reactors require it.
Pharmaceutical Hydrogenation in China’s Hydrogen Market
China operates the world's largest alkaline electrolyser manufacturing base and is the dominant market for AWE systems globally. With aggressive renewable energy deployment in Inner Mongolia, Xinjiang, and coastal provinces, China's green hydrogen capacity is scaling from GW to tens of GW. The domestic alkaline electrolyser market is intensely competitive, creating demand for differentiated membrane technology.
For Chinese electrolyser OEMs competing on efficiency specs, IONZERA's 3x lower resistance offers a meaningful performance differentiator. The mesh-free design and advanced nanocomposite composition represent a next-generation technology leap for stacks targeting export markets with stringent performance requirements.
Lower Resistance
Thinner Profile
PERFORMANCE ADVANTAGE
Why IONZERA for Pharmaceutical Hydrogenation in China
Electrolytic hydrogen from water splitting is inherently free of carbon monoxide, sulfur, and hydrocarbon impurities that can poison precious metal hydrogenation catalysts used in API manufacturing.
Shipping & Logistics
Air freight from India to Shanghai/Beijing in 3-5 business days. Sea freight 2-3 weeks.
Area Resistance
3x LOWERThickness
20% THINNERFrequently Asked Questions
Why choose IONZERA for pharmaceutical hydrogenation in China?
IONZERA delivers 3x lower ionic resistance than Zirfon, making it ideal for pharmaceutical hydrogenation applications in China. For Chinese electrolyser OEMs competing on efficiency specs, IONZERA's 3x lower resistance offers a meaningful performance differentiator.
How does IONZERA compare to Chinese domestic AWE membranes?
IONZERA's proprietary PSU-TiO2-GO nanocomposite achieves 0.09-0.1 ohm-cm2 area resistance, which is significantly lower than most domestic Chinese AWE separators. The mesh-free architecture and graphene oxide enhancement provide a technology generation leap.
Can Chinese electrolyser OEMs integrate IONZERA as a drop-in membrane?
Yes. IONZERA operates in standard 30 wt% KOH electrolyte at up to 45 degrees C and is compatible with standard AWE stack designs. It is a direct replacement for existing separators without requiring frame or system modifications.
EXPLORE MORE
Request Pharmaceutical Hydrogenation Samples for China
Contact G-Hexa for IONZERA pharmaceutical hydrogenation membrane samples, technical specifications, and volume pricing for China-based projects.
Request Sample